AFX logo

Carl Zeiss Meditec AG Stock Price

XTRA:AFX Community·€3.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 48 Fair Values set on narratives written by author

AFX Share Price Performance

€43.36
-12.09 (-21.80%)
€53.61
Fair Value
€43.36
-12.09 (-21.80%)
19.1% undervalued intrinsic discount
€53.61
Fair Value
Price €43.36
AnalystConsensusTarget €53.61
AnalystLowTarget €39.53
AnalystHighTarget €74.88

AFX Community Narratives

AnalystConsensusTarget·
Fair Value €53.61 19.1% undervalued intrinsic discount

VISUMAX 800 Approval In China Will Strengthen Future Market Position

1users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AnalystLowTarget·
Fair Value €36.93 17.4% overvalued intrinsic discount

Regulatory Uncertainty And Trade Tensions Will Depress Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value €69 37.2% undervalued intrinsic discount

Digital And AI Advances Will Expand Global Eye Care Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
€36.93
17.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
4.55% p.a.
Profit Margin
8.96%
Future PE
17.15x
Share price in 2028
€43.08
€53.61
19.1% undervalued intrinsic discount
Revenue growth
6.27% p.a.
Profit Margin
10.2%
Future PE
20.85x
Share price in 2028
€62.63

Updated Narratives

AFX logo

VISUMAX 800 Approval In China Will Strengthen Future Market Position

Fair Value: €53.61 19.1% undervalued intrinsic discount
27 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AFX logo

Regulatory Uncertainty And Trade Tensions Will Depress Margins

Fair Value: €36.93 17.4% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AFX logo

Digital And AI Advances Will Expand Global Eye Care Markets

Fair Value: €69 37.2% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

1 Risk
3 Rewards

Carl Zeiss Meditec AG Key Details

€2.2b

Revenue

€1.0b

Cost of Revenue

€1.1b

Gross Profit

€983.4m

Other Expenses

€150.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Dec 11, 2025
1.72
52.00%
6.89%
28.5%
View Full Analysis

About AFX

Founded
1846
Employees
5713
CEO
Maximilian Foerst
WebsiteView website
www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics, as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of ZEISS Group.

Recent AFX News & Updates

Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital

Nov 01
Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital

Carl Zeiss Meditec AG's (ETR:AFX) Share Price Matching Investor Opinion

Aug 29
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Matching Investor Opinion

Recent updates

No updates